Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients

Background/Aims Oral EDP-514 is a potent core protein inhibitor of hepatitis B virus (HBV) replication, which produced a >4-log viral load reduction in HBV-infected chimeric mice with human liver cells. This study evaluated the safety, pharmacokinetics, and antiviral activity of three doses of ED...

Full description

Bibliographic Details

Published in:	Clinical and Molecular Hepatology
Main Authors:	Man-Fung Yuen, Wan-Long Chuang, Cheng-Yuan Peng, Wen-Juei Jeng, Wei-Wen Su, Ting-Tsung Chang, Chi-Yi Chen, Yao-Chun Hsu, Guy De La Rosa, Alaa Ahmad, Ed Luo, Annie L. Conery
Format:	Article
Language:	English
Published:	Korean Association for the Study of the Liver 2024-07-01
Subjects:	chronic hepatitis b hepatitis b virus core protein inhibitor pharmacokinetics safety
Online Access:	http://e-cmh.org/upload/pdf/cmh-2023-0535.pdf